Roflumilast

$ 15.00 /1kg

Min. Order1kg
Purity99%
Cas No162401-32-3
Supply Ability1000kg
Update time2022-12-26

Hebei Duling International Trade Co. LTD

3YR

China

Chemical Properties

Product Name	Roflumilast
CAS No	162401-32-3
EC-No	685-382-2
Min. Order	1kg
Purity	99%
Supply Ability	1000kg
Release date	2022/12/26

Company Profile Introduction

Recommended supplier

Roflumilast

$50.00/1kg

Anhui Ruihan Technology Co., Ltd

Roflumilast

$0.00/25KG

Hebei Mojin Biotechnology Co., Ltd

VIP5Y

Roflumilast

$10.00/1kg

Henan Bao Enluo International TradeCo.，LTD

Roflumilast

$20.00/1KG

XINGTAI XINGJIU NEW MATERIAL TECHNOLOGY CO., LTD

Roflumilast

$10.00/1g

Qiuxian Baitai New Material Co., LTD

Roflumilast

$15.00/1KG

Zhuozhou Wenxi import and Export Co., Ltd

Roflumilast

$25.00/1ASSAYS

Hebei Guanlang Biotechnology Co., Ltd.

VIP6Y

Roflumilast

$10.00/1KG

Hebei Guanlang Biotechnology Co,.LTD

VIP4Y

Roflumilast USP/EP/BP

$1.10/1g

Dideu Industries Group Limited

VIP4Y

Roflumilast

$0.00/1KG

WUHAN CIRCLE POWDER TECHNOLOGY CO.,LTD

Send Inquriy

Product Name:	Roflumilast
Synonyms:	ROFLUMILAST;3-(Cyclopropylmethoxy)-N-(3,5-dichloro-4-pyridinyl)-4-(difluoromethoxy)benzamide;B 9302-107;BY 217;BYK 20869;Daxas;Roflumilast / 3-(cyclopropylmethoxy)-N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)benzamide;3-(Cyclopropylmethoxy)-N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)benzamide
CAS:	162401-32-3
MF:	C17H14Cl2F2N2O3
MW:	403.21
EINECS:	685-382-2
Product Categories:	Roflumilast;Daxas;Inhibitors;Intermediates & Fine Chemicals;APIs;API;All Inhibitors;Pharmaceuticals
Mol File:	162401-32-3.mol

Uses	Selective phosphodiesterase 4(PDE4) inhibitor. Antiasthmatic; in treatment of chronic obstructive pulmonary disease
Uses	Roflumilast (Daxas) is a selective inhibitor of PDE4 with IC50 of 0.2-4.3 nM.
Uses	ophthalmic solution
Uses	Roflumilast is a selective, long-acting PDE-4 inhibitor approved in 2010 for the treatment of inflammatory conditions of the lungs such as asthma and chronic obstructive pulmonary disorder. Marketed under the trade name Daxas?, roflumilast was developed by researchers at the University of Liverpool in partnership with Nycomed. Although the dose-limiting side effects of the drug are mild nausea, diarrhea, and weight loss, these symptoms subsided after a few weeks of treatment.

Roflumilast

Company Profile Introduction

You may like

Recommended supplier